How many patients will be prescribed Elevidys by the end of 2024? | Categorical | | | 6 months ago | |
Which analyst's price target for Sarepta will be closest to actual stock price on December 31, 2024? | Categorical | | | 6 months ago | |
Will Sarepta's stock price reach BofA's target of $213 by December 31, 2024? | Binary | | | 6 months ago | |
Will Sarepta's Elevidys annual revenue surpass $700 million by 2025? | Binary | | | 6 months ago | |
Sarepta's market cap ranking among biotechnology companies by end of 2024? | Categorical | | | 6 months ago | |
Elevidys generates $500mn or more in revenue by end of 2024? | Binary | | | 6 months ago | |
Number of new gene therapy approvals by FDA by end of 2024? | Categorical | | | 6 months ago | |
Full FDA approval for Elevidys for non-ambulatory patients by end of 2024? | Binary | | | 6 months ago | |
Sarepta stock price increases by 50% or more by end of 2024? | Binary | | | 6 months ago | |
Will Sarepta's stock reach $213 by end of 2024? | Binary | | | 6 months ago | |
What will be Sarepta's stock price range by end of 2024? | Categorical | | | 6 months ago | |
What will be the revenue from Elevidys gene therapy by end of 2024? | Categorical | | | 6 months ago | |
Will FDA revisit Elevidys approval in 2024? | Binary | | | 6 months ago | |
Other manufacturers produce KP.2 vaccine for fall 2024? | Binary | | | 6 months ago | |
Top COVID-19 vaccine market share holder by end of 2024? | Categorical | | | 6 months ago | |
Predominant COVID-19 strain in U.S. for 2024-2025 season? | Categorical | | | 6 months ago | |
Novavax JN.1 vaccine distribution by mid-July 2024? | Binary | | | 6 months ago | |
FDA approval of KP.2 vaccine for 2024-2025 season? | Binary | | | 6 months ago | |
First distributor of KP.2 vaccine in the U.S.? | Categorical | | | 6 months ago | |
FDA reopens review of Sarepta's Elevidys by end of 2024? | Binary | | | 6 months ago | |
What will be Elevidys' peak annual revenue by the end of 2026? | Categorical | | | 6 months ago | |
Percentage increase in DMD patients treated with Elevidys by end of 2024? | Categorical | | | 6 months ago | |
Will Elevidys face additional regulatory scrutiny in 2024? | Binary | | | 6 months ago | |
Will the FDA issue a new safety warning for mRNA COVID-19 vaccines by the end of 2024? | Binary | | | 4 months ago | |
Will Moderna face a significant lawsuit over cancer claims by the end of 2024? | Binary | | | 4 months ago | |
Sarepta's stock price increases by 20% or more post-approval by end of 2024? | Binary | | | 6 months ago | |
Will the FDA revise its approval for Elevidys by the end of 2024? | Binary | | | 6 months ago | |
How many emergency room visits due to mRNA COVID-19 vaccines will be reported by the end of 2024? | Categorical | | | 4 months ago | |
Will reported adverse events related to mRNA COVID-19 vaccines exceed 750,000 by the end of 2024? | Binary | | | 4 months ago | |
What will be the outcome of FDA's ongoing review of mRNA COVID-19 vaccines by the end of 2024? | Categorical | | | 4 months ago | |
How many hospitalizations due to mRNA COVID-19 vaccines will be reported by the end of 2024? | Categorical | | | 4 months ago | |
Sarepta's stock price reaction to Elevidys approval by end of Q3 2024? | Categorical | | | 6 months ago | |
Major legal challenge against FDA's Elevidys approval by end of 2024? | Binary | | | 6 months ago | |
Public and expert opinion on Elevidys one year post-approval? | Categorical | | | 6 months ago | |
Career outcomes for Peter Marks due to Elevidys approval by end of 2024? | Categorical | | | 6 months ago | |
What will be the market response to Elevidys gene therapy by end of 2024? | Categorical | | | 6 months ago | |
